Q BioMed Inc (OTCMKTS:QBIO), the biomedical group, has announced another milestone - the first patient dosing of its cancer bone pain drug Strontium89.
The firm expects this to be the first of thousands of patients dosed with the FDA approved non-opioid drug in the coming years.
"With an estimated 10 million people living with bone metastases, we expect that even a small penetration in this market will have dramatic effects on QBioMed’s future," said Q BioMed CEO Denis Corin.
WATCH: Full interview: Q BioMed infuses first patient with its FDA-approved cancer bone pain drug
"We believe this drug has a very important role to play as clinicians move toward proven non-opioid therapeutics for pain palliation for patients with painful bone metastases."
This first dosing in a commercial setting comes after Q Biomed completed an initial commercial production run and shipment last month (February).
Due to the opioid crisis, clinicians and patients are looking for pain management alternatives. Strontium89, which can be administered every three months, was shown in numerous clinical trials to relieve pain in over 70% of patients who received the treatment.
Q BioMed plans to launch the drug in global markets, including Europe, later this year.
Contact the author at giles@proactiveinvestors.com